Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PMS in the perimenopause.

Ismail Hassan1, Khaled M K Ismail, Shaughn O'Brien

  • 1Academic Unit of Obstetrics and Gynaecology, Keele University Medical School, University Hospital of North Staffordshire NHS Trust, Stoke on Trent ST4 6QG, UK.

The Journal of the British Menopause Society
|January 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sn-MOF/Zn-MOF composite electrode with interfacial synergy for high-performance battery-supercapacitor hybrid devices.

RSC advances·2026
Same author

COVID Recovery Laparoscopic Simulation Program for Gynecological Registrars-Trainee Perceptions of Regional Model.

Journal of minimally invasive gynecology·2024
Same author

New approaches suggest term and preterm human fetal membranes may have distinct biomechanical properties.

Scientific reports·2022
Same author

Mifepristone and misoprostol versus placebo and misoprostol for resolution of miscarriage in women diagnosed with missed miscarriage: the MifeMiso RCT.

Health technology assessment (Winchester, England)·2021
Same author

A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder.

Psychoneuroendocrinology·2021
Same author

Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2020
Same journal

Mammographic density: a hormonally responsive risk factor for breast cancer.

The journal of the British Menopause Society·2006
Same journal

Reproductive ageing, sex steroids and depression.

The journal of the British Menopause Society·2006
Same journal

Controversies in the use of adjuvant trastuzumab (Herceptin).

The journal of the British Menopause Society·2006
Same journal

Health benefits of weight reduction in postmenopausal women: a systematic review.

The journal of the British Menopause Society·2006
Same journal

Cognitive function testing: the case for standardization and automation.

The journal of the British Menopause Society·2006
Same journal

Hysterectomy and sexual function.

The journal of the British Menopause Society·2006
See all related articles

Managing premenstrual syndrome (PMS) and perimenopause together is challenging. Understanding their differences and similarities aids clinicians in improving women's quality of life through targeted treatment strategies.

Area of Science:

  • Reproductive endocrinology
  • Women's health
  • Gynecology

Background:

  • Premenstrual syndrome (PMS) and perimenopause present distinct management challenges.
  • Co-occurrence of PMS and perimenopause symptoms complicates treatment and impacts quality of life.
  • Recognizing similarities and differences is crucial for effective clinical management.

Purpose of the Study:

  • To review the difficulties encountered in managing women with both PMS and perimenopause.
  • To provide a suggested management strategy for this patient population.
  • To improve understanding of the interplay between hormonal changes in PMS and perimenopause.

Main Methods:

  • Review of existing literature on PMS and perimenopause.
  • Analysis of symptom presentation and hormonal influences.

Related Experiment Videos

  • Discussion of treatment approaches, including hormone therapy and selective serotonin re-uptake inhibitors (SSRIs).

    • Main Results:

    • Perimenopausal symptoms stem from declining estrogen and irregular ovulation, relieved by estrogen administration.
    • PMS is linked to progesterone sensitivity post-ovulation, treatable by suppressing ovulation or using SSRIs.
    • Estrogen therapy for perimenopause necessitates progestogen, potentially exacerbating PMS symptoms.

    Conclusions:

    • Effective management requires differentiating between PMS and perimenopause symptoms.
    • Hormonal management strategies must carefully consider the potential for progestogens to worsen PMS.
    • Integrated treatment approaches are necessary to address both conditions concurrently and improve patient outcomes.